Michael G. Tramontana, Ph.D., Associate Professor of Psychiatry, Neurology, and Pediatrics, was recently awarded funding from Shire Pharmaceuticals for an investigator-initiated research proposal entitled, "Treatment Outcomes with Lisdexamfetamine Dimesylate (Vyvanse) in Children with Traumatic Brain Injury-Related Attention Deficits." It will be a two-year study that will extend and refine the work of a previous clinical trial led by Dr. Tramontana that dealt primarily with adults (published in Brain Injury, 2014, 28 (11), 1461-1472). The new study will focus on children with TBI ranging from 6 to 16 years of age.
